AMGN — AMGEN INC catalysts
Next verified catalyst
2026-06-22 — A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult an · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-06-22 today
ESTIMATED |
READOUT
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab i
Phase 3 · Atopic Dermatitis |
AMGN AMGEN INC | Rocatinlimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-08-06 in 2mo
ESTIMATED |
READOUT
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderat
Phase 3 · Plaque Psoriasis |
AMGN AMGEN INC | Apremilast |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-08-19 in 2mo
ESTIMATED |
READOUT
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With
Phase 3 · Sjogren's Syndrome |
AMGN AMGEN INC | Dazodalibep |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-10-22 in 4mo
ESTIMATED |
READOUT
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndro
Phase 3 · Sjögren's Syndrome (SS) |
AMGN AMGEN INC | Dazodalibep |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-10-31 in 4mo
ESTIMATED |
READOUT
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC
Phase 2 · MTAP-deleted NSCLC |
AMGN AMGEN INC | anvumetostat |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|